The impact of cyclin D1 overexpression on the prognosis of bladder cancer: A meta-analysis

World Journal of Surgical Oncology

Volumn 12, Issue 1, 2014, Pages

  Ren, Baoming ^a   Li, Wenjun ^a   Yang, Yanping ^b   Wu, Songdi ^a  

^a First Hosp of Xi'an Jiaotong Univ   (China)

^b Shaanxi Polytechnic Institute   (China)

Author keywords

Bladder cancer; Cyclin D1; Meta analysis; Prognosis

Indexed keywords

CYCLIN D1;

ARTICLE; BIBLIOGRAPHIC DATABASE; BLADDER CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CLINICAL ASSESSMENT; DISEASE FREE SURVIVAL; DISEASE SEVERITY; GENE OVEREXPRESSION; HAZARD RATIO; HUMAN; IMMUNOHISTOCHEMISTRY; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); MUSCLE INVASIVE BLADDER CANCER; NEWCASTLE OTTAWA QUALITY ASSESSMENT SCALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PUBLISHING; QUALITY CONTROL; RATING SCALE; RECURRENCE FREE SURVIVAL; SYSTEMATIC REVIEW;

CYCLIN D1; HUMANS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84897438497     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-12-55     Document Type: Article

References (32)

1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009, 27:289-293. 10.1007/s00345-009-0383-3, 2694323, 19219610.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
3. Baumgart E, Cohen MS, Silva Neto B, Jacobs MA, Wotkowicz C, Rieger-Christ KM, Biolo A, Zeheb R, Loda M, Libertino JA, Summerhayes IC. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res 2007, 13:1685-1694. 10.1158/1078-0432.CCR-06-2330, 17363521.
4. Shariat SF, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Rigaud J, Müller SC, Lerner SP, Montorsi F, Sagalowsky AI, Cote RJ, Lotan Y. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int 2010, 105:489-495. 10.1111/j.1464-410X.2009.08742.x, 19659466.
5. Fauconnet S, Bernardini S, Lascombe I, Boiteux G, Clairotte A, Monnien F, Chabannes E, Bittard H. Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer. Oncol Rep 2009, 21:1495-1504.
6. Strauss M, Lukas J, Bartek J. Unrestricted cell cycling and cancer. Nat Med 1995, 1:1245-1246. 10.1038/nm1295-1245, 7489399.
7. Niehans GA, Kratzke RA, Froberg MK, Aeppli DM, Nguyen PL, Geradts J. G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder. Br J Cancer 1999, 80:1175-1184. 10.1038/sj.bjc.6990483, 2362363, 10376969.
8. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097. 10.1371/journal.pmed.1000097, 2707599, 19621072.
9. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834. 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8, 9921604.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
11. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101. 10.2307/2533446, 7786990.
12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634. 10.1136/bmj.315.7109.629, 2127453, 9310563.
13. Shin KY, Kong G, Kim WS, Lee TY, Woo YN, Lee JD. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer 1997, 75:1788-1792. 10.1038/bjc.1997.305, 2223624, 9192983.
14. Liukkonen T, Lipponen P, Raitanen M, Kaasinen E, Ala-Opas M, Rajala P, Kosma VM. Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer. Finbladder Group. Urol Res 2000, 28:285-292.
15. Takagi Y, Takashi M, Koshikawa T, Sakata T, Ohshima S. Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor. Int J Urol 2000, 7:366-372. 10.1046/j.1442-2042.2000.00212.x, 11144504.
16. Tut VM, Braithwaite KL, Angus B, Neal DE, Lunec J, Mellon JK. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Br J Cancer 2001, 84:270-275. 10.1054/bjoc.2000.1557, 2363716, 11161387.
17. Sgambato A, Migaldi M, Faraglia B, De Aloysio G, Ferrari P, Ardito R, De Gaetani C, Capelli G, Cittadini A, Trentini GP. Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome. Int J Cancer 2002, 97:671-678. 10.1002/ijc.10055, 11807796.
18. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Requena MJ, Montironi R. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol 2004, 122:444-452. 10.1309/LTFU3UUMBY095HUM, 15362377.
19. Mhawech P, Greloz V, Oppikofer C, Szalay-Quinodoz I, Herrmann F. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression. Cancer 2004, 100:2367-2375. 10.1002/cncr.20306, 15160340.
20. Galmozzi F, Rubagotti A, Romagnoli A, Carmignani G, Perdelli L, Gatteschi B, Boccardo F. Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer. J Cancer Res Clin Oncol 2006, 132:757-764. 10.1007/s00432-006-0123-7, 16804724.
21. Yurakh AO, Ramos D, Calabuig-Farinas S, Lopez-Guerrero JA, Rubio J, Solsona E, Romanenko AM, Vozianov AF, Pellin A, Llombart-Bosch A. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol 2006, 50:506-515. discussion 515, 10.1016/j.eururo.2006.03.027, 16624482.
22. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol 2007, 25:468-475. 10.1016/j.urolonc.2006.09.011, 18047954.
23. Lee K, Jung ES, Choi YJ, Lee KY, Lee A. Expression of pRb, p53, p16 and cyclin D1 and their clinical implications in urothelial carcinoma. J Korean Med Sci 2010, 25:1449-1455. 10.3346/jkms.2010.25.10.1449, 2946654, 20890425.
24. Levidou G, Saetta AA, Karlou M, Thymara I, Pratsinis H, Pavlopoulos P, Isaiadis D, Diamantopoulou K, Patsouris E, Korkolopoulou P. D-type cyclins in superficial and muscle-invasive bladder urothelial carcinoma: correlation with clinicopathological data and prognostic significance. J Cancer Res Clin Oncol 2010, 136:1563-1571. 10.1007/s00432-010-0814-y, 20174823.
25. Behnsawy HM, Miyake H, Abdalla MA, Sayed MA, Ahmed Ael F, Fujisawa M. Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection. Urol Oncol 2011, 29:495-501. 10.1016/j.urolonc.2009.08.002, 19914103.
26. Olsson H, Hultman P, Monsef N, Rosell J, Jahnson S. Immunohistochemical evaluation of cell cycle regulators: impact on predicting prognosis in stage t1 urinary bladder cancer. ISRN Urol 2012, 2012:379081. 3523551, 23304558.
27. Fristrup N, Birkenkamp-Demtroder K, Reinert T, Sanchez-Carbayo M, Segersten U, Malmstrom PU, Palou J, Alvarez-Mugica M, Pan CC, Ulhoi BP, Borre M, Ørntoft TF, Dyrskjøt L. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol 2013, 182:339-349. 10.1016/j.ajpath.2012.10.017, 23201130.
28. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007, 6:24. 1851974, 17407548.
29. Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, Zagozdzon A, Goswami T, Wang YE, Clark AB, Kunkel TA, van Harn T, Xia B, Correll M, Quackenbush J, Livingston DM, Gygi SP, Sicinski P. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 2011, 474:230-234. 10.1038/nature10155, 3134411, 21654808.
30. Xu XL, Chen SZ, Chen W, Zheng WH, Xia XH, Yang HJ, Li B, Mao WM. The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta-analysis. Breast Cancer Res Treat 2013, 139:329-339. 10.1007/s10549-013-2563-5, 23670132.
31. Zhao J, Li L, Wei S, Gao Y, Chen Y, Wang G, Wu Z. Clinicopathological and prognostic role of cyclin D1 in esophageal squamous cell carcinoma: a meta-analysis. Dis Esophagus 2012, 25:520-526. 10.1111/j.1442-2050.2011.01278.x, 22098104.
32. Rainsbury JW, Ahmed W, Williams HK, Roberts S, Paleri V, Mehanna H. Prognostic biomarkers of survival in oropharyngeal squamous cell carcinoma: systematic review and meta-analysis. Head Neck 2013, 35:1048-1055. 10.1002/hed.22950, 22997051.